Targeting sphingolipid metabolism to treat cancer
Bioactive sphingolipids, or SLs, such as ceramide and sphingosine-1-phosphate, long have been implicated in cell death, cell survival and cell growth. This took on greater significance when researchers discovered that SL metabolism is dysregulated in many cancers, leading to the hypothesis that an altered SL balance helps drive the uncontrolled growth and evasion of cell death that are hallmarks of cancer. It also suggested the tantalizing possibility that restoring the balance of SLs could be an effective therapeutic. However, despite considerable effort, the promise of targeting SL metabolism for cancer treatment has yet to be realized fully.
To date, development of SL-based therapeutics has been pursued in two main ways: using exogenous ceramide, or Cer — the archetypal anti-growth, pro-death SL — and targeting of SL enzymes with increased expression in cancer. While there is considerable evidence that exogenous Cer effectively kills cancer cells in the laboratory, it also affects noncancerous cells. This has been circumvented in part by incorporating Cer into coated nanoliposomes, which have shown promise in preclinical models and are in early clinical trials for safety. However, exogenous Cer also upregulates its own catabolic pathways that can promote a resistance phenotype. As these pathways also can be increased in aggressive cancers, the broader utility of Cer treatments across cancers is unclear.
The best example of the SL enzyme–targeting approach involves the sphingosine kinases 1 and 2, or SK 1 and 2, which are overexpressed in many cancers and whose product, sphingosine-1-phosphate, has been implicated in many pro-tumor biologies, prompting efforts to develop potent and isoform-specific SK inhibitors. However, treatment of many cancer cells with PF-543 — a nanomolar potency SK1 inhibitor — had no effect on cancer cell viability, and studies with other SK inhibitors suggested their anti-cancer efficacy could be due to off-target effects. Thus, researchers are reexamining efforts to develop SK as a general anticancer target.
As our understanding of SL signaling increases, we need to use this knowledge to refine our approach to SL-based therapeutics. For example, there is growing evidence that the same lipid can have different functions depending on where it is generated in the cell — for example, in the endoplasmic reticulum versus the plasma membrane — or the particular species that is produced, such as C16-Cer versus C18-Cer. Thus, more targeted alterations in SL levels may be necessary to achieve the desired anti-cancer response.
Similarly, we need to look beyond a magic-bullet SL therapeutic and consider that different SL targets may be relevant for specific cancers and cancer subtypes — indeed, recent evidence suggests that this might be the case for SKs. Finally, the interconnected nature of the SL metabolism makes it difficult to separate primary driver events from bystander effects. Thus, we need to look beyond enzyme expression to define tumor-specific vulnerabilities in the SL network.
Overall, the potential for cancer therapeutics targeting SL metabolism remains high, particularly as most metabolic outputs are driven enzymatically and are thus highly druggable. We have made strides along the path to translation. We still have a long way to go, but as we gain greater appreciation of the biological roles and regulation of SL, I am confident that ultimately we will succeed.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Cracking the recipe for perfect plant-based eggs
It involves finding just the right proteins. With new ingredients and processes, the next generation of substitutes will be not just more egg-like, but potentially more nutritious.
MSU researchers leverage cryo-EM for decades-in-the-making breakthrough
Lee Kroos and Ben Orlando have reported the first high-resolution experimentally determined structures of the intramembrane protease SpolVFB.
From the Journals: MCP
Rapid and precise SARS-CoV-2 detection using mass spec. Mapping brain changes from drug addiction. Decoding plant osmotic stress response. Read about recent MCP papers on these topics.
What seems dead may not be dead
Vincent Tagliabracci will receive the Earl and Thressa Stadtman Distinguished Scientist Award at the ASBMB Annual Meeting, April 12–15 in Chicago.
'You can't afford to be 15 years behind the parasite'
David Fidock will receive the Alice and C.C. Wang Award in Molecular Parasitology at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Elucidating how chemotherapy induces neurotoxicity
Andre Nussenzweig will receive the Bert and Natalie Vallee Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.